The company anticipates that the gross proceeds will significantly bolster its financial position, allowing it to advance its clinical programs and enhance its operational capabilities. Following the completion of this financing, Alto expects to have approximately $275 million in cash and cash equivalents, providing a solid foundation for its upcoming clinical initiatives.
In conjunction with the financing, Alto has agreed to expand its Board of Directors to seven members, reflecting its commitment to strong governance and strategic oversight as it navigates this critical phase of growth. The company has engaged several reputable placement agents, including Jefferies LLC and BofA Securities, to facilitate this transaction, ensuring a robust execution of the financing process.
The private placement is structured to comply with applicable securities laws, and the company has committed to filing a registration statement with the SEC to register the resale of the shares issued under the agreement. This move is expected to enhance liquidity for investors and facilitate a smoother transition into the public market for the newly issued shares.
Alto's CEO, Amit Etkin, expressed optimism regarding the financing, stating, "This financing is expected to provide the resources needed to advance ALTO-207 through a Phase 3 study, a major step toward realizing the potential of this program. We appreciate the support from this top-tier investor group, which we believe reflects the growing confidence in Alto’s precision neuroscience strategy and in ALTO-207 as a potential treatment option for patients with significant unmet need."
The successful completion of this financing marks a pivotal moment for Alto Neuroscience, positioning the company to make significant strides in the development of innovative treatments for neuropsychiatric disorders. With a clear focus on advancing ALTO-207, Alto aims to address the pressing needs of patients suffering from TRD, a condition that has long been underserved in the pharmaceutical landscape.
